Safety Netting for Starting Rivaroxaban

Pre-Initiation Assessment

The European Society of Cardiology recommends assessing renal function to determine appropriate dosing and educating patients on bleeding recognition when initiating rivaroxaban, as well as avoiding concomitant medications that increase bleeding risk and establishing a monitoring schedule for renal and hepatic function 1, 2
Rivaroxaban is contraindicated in patients with severe liver disease, any degree of hepatic coagulopathy, according to the American Association for the Study of Liver Diseases 3
Rivaroxaban undergoes hepatic metabolism via CYP3A4-dependent and independent mechanisms, as noted by the National Comprehensive Cancer Network 4

The European Heart Society recommends screening for active bleeding, which is an absolute contraindication to initiation, and identifying high-risk features such as age ≥75 years, history of gastrointestinal bleeding, peptic ulcer disease, prior intracranial hemorrhage 1, 2
Patients ≥75 years with atrial fibrillation or VTE have increased gastrointestinal bleeding risk with rivaroxaban compared to warfarin, according to the European Heart Society 1, 2

The American College of Cardiology recommends avoiding concomitant use with antiplatelets, NSAIDs, SNRIs, SSRIs, other anticoagulants, or thrombolytics, unless specifically indicated for acute coronary syndrome or mechanical heart valves 1, 2
Review for CYP3A4 inhibitors/inducers that may affect rivaroxaban levels, as suggested by the National Comprehensive Cancer Network 4

The National Comprehensive Cancer Network recommends preferring LMWH over rivaroxaban in patients with gastric or gastroesophageal tumors due to excess major bleeding risk 5
If rivaroxaban must be used in gastrointestinal cancer, apixaban may be safer than rivaroxaban based on comparative bleeding data, according to the National Comprehensive Cancer Network 5

For moderate renal impairment (CrCl 30-49 mL/min), the American College of Cardiology recommends reducing maintenance dose from 20 mg to 15 mg once daily after initial treatment phase for VTE, as noted by Praxis Medical Insights 6

The European Heart Society recommends educating patients to recognize and immediately report signs of bleeding, such as unusual bruising, blood in urine/stool, black tarry stools, coughing blood, severe headache, dizziness, weakness 1, 2

The American College of Cardiology recommends assessing renal function 2-3 times per year for patients with moderate renal impairment (CrCl 30-49 mL/min), as suggested by Praxis Medical Insights 6
Periodic monitoring of hepatic function is recommended, particularly in elderly patients and those with baseline liver disease, according to the European Heart Society 1, 2

The American College of Cardiology recommends not using standard 20 mg maintenance dose in patients with CrCl 30-49 mL/min, as this increases bleeding risk, as noted by Praxis Medical Insights 6
Do not combine rivaroxaban with antiplatelet agents unless there is a specific cardiovascular indication, according to the European Heart Society 1, 2
Avoid prescribing rivaroxaban for cancer-associated VTE in patients with gastric/gastroesophageal tumors without considering LMWH alternatives, as recommended by the National Comprehensive Cancer Network 5

Rivaroxaban is approved for stroke prevention in non‑valvular atrial fibrillation, for treatment and secondary prevention of venous thromboembolism (VTE), and for postoperative deep‑vein thrombosis prophylaxis after hip or knee arthroplasty, with dosing that varies by indication and renal function. 7

Standard dose: 20 mg once daily for patients with a CHA₂DS₂‑VASc score ≥ 2. 7
Low‑risk patients: Oral anticoagulation may be considered for a CHA₂DS₂‑VASc score of 1 after individualized bleeding‑risk assessment. 7
Renal‑adjusted dose: Reduce to 15 mg once daily in patients with moderate renal impairment (creatinine clearance 30–49 mL/min) or in those with a high bleeding risk (HAS‑BLED ≥ 3). 7
Contraindication: Rivaroxaban should not be used in patients with severe renal impairment (creatinine clearance < 30 mL/min). 7

Renal assessment: Calculate creatinine clearance using the Cockcroft‑Gault equation before initiating therapy and repeat the assessment 2–3 times per year in patients with moderate renal impairment and annually in those with normal renal function. 7
Normal to mild impairment (CrCl ≥ 50 mL/min): Use the standard dosing regimens described for each indication. 7
Moderate impairment (CrCl 30–49 mL/min):
- Atrial fibrillation – 15 mg once daily.
- VTE maintenance – 15 mg once daily (when indicated).
- Use with heightened monitoring due to increased bleeding risk. 7
Severe impairment (CrCl 15–29 mL/min): Rivaroxaban is avoided according to ESC and NCCN guidance. 7
End‑stage renal disease (CrCl < 15 mL/min or dialysis): Rivaroxaban is contraindicated. 7
Bleeding‑risk scoring: A HAS‑BLED score ≥ 3 identifies patients at high risk of bleeding and should prompt dose‑adjustment or alternative therapy considerations. 7

Rivaroxaban receives a Category 1 recommendation for the treatment of cancer‑associated VTE. 8
Critical exception: Rivaroxaban should be avoided in patients with gastric or gastro‑esophageal tumors because it adds an absolute increase of approximately 2.9 % in major bleeding events. 8
For gastrointestinal malignancies, low‑molecular‑weight heparin (LMWH) is preferred over rivaroxaban. 8
When a direct oral anticoagulant is required in gastrointestinal cancer, apixaban is considered a safer alternative to rivaroxaban. 8